Retraction Note: Transcriptional repression of SOCS3 mediated by IL-6/STAT3 signaling via DNMT1 promotes pancreatic cancer growth and metastasis(J Exp Clin Cancer Res, (2016), 35, (27), 10.1186/s13046-016-0301-7);Transcriptional repression of SOCS3 mediated by IL-6/STAT3 signaling via DNMT1 promotes pancreatic cancer growth and metastasis

Journal of Experimental and Clinical Cancer Research

Volumn 35, Issue 1, 2016, Pages

  Huang, Li ^a   Hu, Bin ^a   Ni, Jianbo ^a   Wu, Jianghong ^a   Jiang, Weiliang ^a   Chen, Congying ^a   Yang, Lijuan ^a   Zeng, Yue ^a   Wan, Rong ^a   Hu, Guoyong ^a   Wang, Xingpeng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

DNA Methyltransferase 1; Interleukin 6; Methylation; Pancreatic ductal adenocarcinoma; Signal transducer and activator of transcription 3; Suppressor of cytokine signaling 3

Indexed keywords

DNA METHYLTRANSFERASE 1; INTERLEUKIN 6; STAT3 PROTEIN; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; IL6 PROTEIN, HUMAN; SOCS3 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ADULT; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENICITY; CONTROLLED STUDY; DNA METHYLATION; DNMT1 GENE; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IL 6 GENE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAT3 GENE; TISSUE MICROARRAY; TRANSCRIPTION REGULATION; TRANSCRIPTION TERMINATION; TUMOR INVASION; TUMOR PROMOTION; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; CANCER TRANSPLANTATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MOUSE; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; MALE; MICE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING 3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANSCRIPTION, GENETIC;

EID: 84959550810     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-023-02595-3     Document Type: Erratum

References (56)

1. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605-17. doi: 10.1056/NEJMra0901557.
2. Muniraj T, Jamidar PA, Aslanian HR. Pancreatic cancer: a comprehensive review and update. Dis Mon. 2013;59(11):368-402. doi: 10.1016/j.disamonth.2013.08.001.
3. Vonderheide RH, Bayne LJ. Inflammatory networks and immune surveillance of pancreatic carcinoma. Curr Opin Immunol. 2013;25(2):200-5. doi: 10.1016/j.coi.2013.01.006.
4. Demaria M, Poli V. Pro-malignant properties of STAT3 during chronic inflammation. Oncotarget. 2012;3(4):359-60. doi: 10.18632/oncotarget.482.
5. Kleger A, Perkhofer L, Seufferlein T. Smarter drugs emerging in pancreatic cancer therapy. Ann Oncol. 2014;25(7):1260-70. doi: 10.1093/annonc/mdu013.
6. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-7. doi: 10.1038/nature01322.
7. Gao J, Wang L, Xu J, Zheng J, Man X, Wu H, et al. Aberrant DNA methyltransferase expression in pancreatic ductal adenocarcinoma development and progression. J Exp Clin Cancer Res. 2013;32:86. doi: 10.1186/1756-9966-32-86.
8. Rengucci C, De Maio G, Casadei Gardini A, Zucca M, Scarpi E, Zingaretti C, et al. Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; potential marker of disease recurrence. J Exp Clin Cancer Res. 2014;33:65. doi: 10.1186/s13046-014-0065-x.
9. Holmer R, Goumas FA, Waetzig GH, Rose-John S, Kalthoff H. Interleukin-6: a villain in the drama of pancreatic cancer development and progression. Hepatobiliary Pancreat Dis Int. 2014;13(4):371-80.
10. Masui T, Hosotani R, Doi R, Miyamoto Y, Tsuji S, Nakajima S, et al. Expression of IL-6 receptor in pancreatic cancer: involvement in VEGF induction. Anticancer Res. 2002;22(6c):4093-100.
11. Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res. 2008;18(2):254-67. doi: 10.1038/cr.2008.18.
12. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell. 2009;15(2):91-102. doi: 10.1016/j.ccr.2009.01.002.
13. Shain KH, Yarde DN, Meads MB, Huang M, Jove R, Hazlehurst LA, et al. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res. 2009;69(3):1009-15. doi: 10.1158/0008-5472.can-08-2419.
14. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798-809. doi: 10.1038/nrc2734.
15. Minamoto S, Ikegame K, Ueno K, Narazaki M, Naka T, Yamamoto H, et al. Cloning and functional analysis of new members of STAT induced STAT inhibitor (SSI) family: SSI-2 and SSI-3. Biochem Biophys Res Commun. 1997;237(1):79-83. doi: 10.1006/bbrc.1997.7080.
16. Gao Y, Cimica V, Reich NC. Suppressor of cytokine signaling 3 inhibits breast tumor kinase activation of STAT3. J Biol Chem. 2012;287(25):20904-12. doi: 10.1074/jbc.M111.334144.
17. Wu WY, Kim H, Zhang CL, Meng XL, Wu ZS. Loss of suppressors of cytokine signaling 3 promotes aggressiveness in hepatocellular carcinoma. J Invest Surg. 2014;27(4):197-204. doi: 10.3109/08941939.2013.873098.
18. Wan J, Che Y, Kang N, Wu W. SOCS3 blocks HIF-1alpha expression to inhibit proliferation and angiogenesis of human small cell lung cancer by downregulating activation of Akt, but not STAT3. Molecular Medicine Reports. 2015;12(1):83-92. doi: 10.3892/mmr.2015.3368.
19. Horndasch M, Culig Z. SOCS-3 antagonizes pro-apoptotic effects of TRAIL and resveratrol in prostate cancer cells. Prostate. 2011;71(12):1357-66. doi: 10.1002/pros.21353.
20. Stofas A, Levidou G, Piperi C, Adamopoulos C, Dalagiorgou G, Bamias A, et al. The role of CXC-chemokine receptor CXCR2 and suppressor of cytokine signaling-3 (SOCS-3) in renal cell carcinoma. BMC Cancer. 2014;14:149. doi: 10.1186/1471-2407-14-149.
21. Brender C, Lovato P, Sommer VH, Woetmann A, Mathiesen AM, Geisler C, et al. Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha. Leukemia. 2005;19(2):209-13. doi: 10.1038/sj.leu.2403610.
22. Chen X, Liu L, Mims J, Punska EC, Williams KE, Zhao W, et al. Analysis of DNA methylation and gene expression in radiation-resistant head and neck tumors. Epigenetics. 2015;10(6):545-61. doi: 10.1080/15592294.2015.1048953.
23. Kim MH, Kim MS, Kim W, Kang MA, Cacalano NA, Kang SB, et al. Suppressor of cytokine signaling (SOCS) genes are silenced by DNA hypermethylation and histone deacetylation and regulate response to radiotherapy in cervical cancer cells. PLoS One. 2015;10(4):e0123133. doi: 10.1371/journal.pone.0123133.
24. Wang J, Zhou H, Han Y, Liu X, Wang M, Wang X, et al. SOCS3 methylation in synergy with Reg3A overexpression promotes cell growth in pancreatic cancer. Journal of Molecular Medicine (Berlin, Germany). 2014;92(12):1257-69. doi: 10.1007/s00109-014-1184-8.
25. Wehbe H, Henson R, Meng F, Mize-Berge J, Patel T. Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res. 2006;66(21):10517-24. doi: 10.1158/0008-5472.can-06-2130.
26. Gasche JA, Hoffmann J, Boland CR, Goel A. Interleukin-6 promotes tumorigenesis by altering DNA methylation in oral cancer cells. Int J Cancer. 2011;129(5):1053-63. doi: 10.1002/ijc.25764.
27. Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Kloppel G, et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell. 2011;19(4):456-69. doi: 10.1016/j.ccr.2011.03.009.
28. Auernhammer CJ, Bousquet C, Melmed S. Autoregulation of pituitary corticotroph SOCS-3 expression: characterization of the murine SOCS-3 promoter. Proc Natl Acad Sci U S A. 1999;96(12):6964-9.
29. He B, You L, Xu Z, Mazieres J, Lee AY, Jablons DM. Activity of the suppressor of cytokine signaling-3 promoter in human non-small-cell lung cancer. Clin Lung Cancer. 2004;5(6):366-70. doi: 10.3816/CLC.2004.n.015.
30. Mauer J, Chaurasia B, Goldau J, Vogt MC, Ruud J, Nguyen KD, et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat Immunol. 2014;15(5):423-30. doi: 10.1038/ni.2865.
31. He B, You L, Uematsu K, Matsangou M, Xu Z, He M, et al. Cloning and characterization of a functional promoter of the human SOCS-3 gene. Biochem Biophys Res Commun. 2003;301(2):386-91.
32. Yang XP, Schaper F, Teubner A, Lammert F, Heinrich PC, Matern S, et al. Interleukin-6 plays a crucial role in the hepatic expression of SOCS3 during acute inflammatory processes in vivo. J Hepatol. 2005;43(4):704-10. doi: 10.1016/j.jhep.2005.02.048.
33. Denson LA, Held MA, Menon RK, Frank SJ, Parlow AF, Arnold DL. Interleukin-6 inhibits hepatic growth hormone signaling via upregulation of Cis and Socs-3. Am J Physiol Gastrointest Liver Physiol. 2003;284(4):G646-654. doi: 10.1152/ajpgi.00178.2002.
34. Lebel E, Vallieres L, Rivest S. Selective involvement of interleukin-6 in the transcriptional activation of the suppressor of cytokine signaling-3 in the brain during systemic immune challenges. Endocrinology. 2000;141(10):3749-63. doi: 10.1210/endo.141.10.7695.
35. Lieskovska J, Guo D, Derman E. Growth impairment in IL-6-overexpressing transgenic mice is associated with induction of SOCS3 mRNA. Growth Horm IGF Res. 2003;13(1):26-35.
36. Stauffer JK, Scarzello AJ, Jiang Q, Wiltrout RH. Chronic inflammation, immune escape, and oncogenesis in the liver: a unique neighborhood for novel intersections. Hepatology (Baltimore, Md). 2012;56(4):1567-74. doi: 10.1002/hep.25674.
37. Liao R, Sun J, Wu H, Yi Y, Wang JX, He HW, et al. High expression of IL-17 and IL-17RE associate with poor prognosis of hepatocellular carcinoma. J Exp Clin Cancer Res. 2013;32:3. doi: 10.1186/1756-9966-32-3.
38. Fukuda A, Wang SC, Morris JP, Folias AE, Liou A, Kim GE, et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell. 2011;19(4):441-55. doi: 10.1016/j.ccr.2011.03.002.
39. Wan S, Zhao E, Kryczek I, Vatan L, Sadovskaya A, Ludema G, et al. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology. 2014;147(6):1393-404. doi: 10.1053/j.gastro.2014.08.039.
40. Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC, et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene. 2003;22(3):319-29. doi: 10.1038/sj.onc.1206122.
41. Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14(11):736-46. doi: 10.1038/nrc3818.
42. Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem. 2003;278(16):13740-6. doi: 10.1074/jbc.M210689200.
43. Dhar K, Rakesh K, Pankajakshan D, Agrawal DK. SOCS3 promotor hypermethylation and STAT3-NF-kappaB interaction downregulate SOCS3 expression in human coronary artery smooth muscle cells. Am J Physiol Heart Circ Physiol. 2013;304(6):H776-785. doi: 10.1152/ajpheart.00570.2012.
44. Zhang L, Li J, Li L, Zhang J, Wang X, Yang C, et al. IL-23 selectively promotes the metastasis of colorectal carcinoma cells with impaired Socs3 expression via the STAT5 pathway. Carcinogenesis. 2014;35(6):1330-40. doi: 10.1093/carcin/bgu017.
45. Hino R, Uozaki H, Murakami N, Ushiku T, Shinozaki A, Ishikawa S, et al. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res. 2009;69(7):2766-74. doi: 10.1158/0008-5472.can-08-3070.
46. Liu CC, Lin JH, Hsu TW, Su K, Li AF, Hsu HS, et al. IL-6 enriched lung cancer stem-like cell population by inhibition of cell cycle regulators via DNMT1 upregulation. Int J Cancer. 2015;136(3):547-59. doi: 10.1002/ijc.29033.
47. Wu J, Xu Y, Mo D, Huang P, Sun R, Huang L, et al. Kaposi's sarcoma-associated herpesvirus (KSHV) vIL-6 promotes cell proliferation and migration by upregulating DNMT1 via STAT3 activation. PLoS One. 2014;9(3):e93478. doi: 10.1371/journal.pone.0093478.
48. Li Y, Deuring J, Peppelenbosch MP, Kuipers EJ, de Haar C, van der Woude CJ. IL-6-induced DNMT1 activity mediates SOCS3 promoter hypermethylation in ulcerative colitis-related colorectal cancer. Carcinogenesis. 2012;33(10):1889-96. doi: 10.1093/carcin/bgs214.
49. Ivanov VN, Bhoumik A, Krasilnikov M, Raz R, Owen-Schaub LB, Levy D, et al. Cooperation between STAT3 and c-jun suppresses Fas transcription. Mol Cell. 2001;7(3):517-28.
50. Yuan ZL, Guan YJ, Chatterjee D, Chin YE. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science (New York, NY). 2005;307(5707):269-73. doi: 10.1126/science.1105166.
51. Zhang Q, Wang HY, Marzec M, Raghunath PN, Nagasawa T, Wasik MA. STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc Natl Acad Sci U S A. 2005;102(19):6948-53. doi: 10.1073/pnas.0501959102.
52. Molavi O, Wang P, Zak Z, Gelebart P, Belch A, Lai R. Gene methylation and silencing of SOCS3 in mantle cell lymphoma. Br J Haematol. 2013;161(3):348-56. doi: 10.1111/bjh.12262.
53. Pierconti F, Martini M, Pinto F, Cenci T, Capodimonti S, Calarco A, et al. Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior. Prostate. 2011;71(3):318-25. doi: 10.1002/pros.21245.
54. Niwa Y, Kanda H, Shikauchi Y, Saiura A, Matsubara K, Kitagawa T, et al. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene. 2005;24(42):6406-17. doi: 10.1038/sj.onc.1208788.
55. Huang X, Dai S, Dai J, Xiao Y, Bai Y, Chen B, et al. Luteolin decreases invasiveness, deactivates STAT3 signaling, and reverses interleukin-6 induced epithelial-mesenchymal transition and matrix metalloproteinase secretion of pancreatic cancer cells. OncoTargets and therapy. 2015;8:2989-3001. doi: 10.2147/ott.s91511.
56. Block KM, Hanke NT, Maine EA, Baker AF. IL-6 stimulates STAT3 and Pim-1 kinase in pancreatic cancer cell lines. Pancreas. 2012;41(5):773-81. doi: 10.1097/MPA.0b013e31823cdd10.